Thyroid Eye Disease Market to Accelerate Substantially by 2034, Assesses DelveInsight | Key Companies Developing Therapies - Viridian Therapeutics, Roche, Immunovant, Amgen, Sling Therapeu...
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
period (2024–2034), mainly attributed to new product launches, robust pipeline of emerging therapies, rise in the geriatric population and government support for clinical development. New York, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Thyroid Eye Disease Market to Accelerate Substantially by 2034, Assesses DelveInsight | Key Companies Developing Therapies - Viridian Therapeutics, Roche, Immunovant, Amgen, Sling Therapeutics, ACELYRIN, Tourmaline Bio According to DelveInsight's' estimates, the thyroid eye disease market in 7MM is expected to show good positive growth, during the forecast period (2024–2034), mainly attributed to new product launches, robust pipeline of emerging therapies, rise in the geriatric population and government support for clinical development. DelveInsight's Thyroid Eye Disease Market Insights report includes a comprehensive understanding of current treatment practices, thyroid eye disease emerging drugs, market share of individual therapies, and current an
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at BTIG Research from $56.00 to $61.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.MarketBeat
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $44.00. They now have an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $25.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock [Yahoo! Finance]Yahoo! Finance
VRDN
Earnings
- 8/8/24 - Miss
VRDN
Sec Filings
- 9/30/24 - Form 4
- 9/30/24 - Form 4
- 9/17/24 - Form 4
- VRDN's page on the SEC website